Multi-year agreement focuses on the manufacture of multiple CAR-Treg product candidates for Phase 1/2 clinical studies Partnership builds on long-term…
OXFORD, UK and CLEVELAND, Ohio, US, 24th September 2024 – The Oxford-Harrington Rare Disease Centre (‘OHC’), a partnership between the…
PARIS, Sept. 24, 2024 (GLOBE NEWSWIRE) -- AlgoTherapeutix (AlgoTx), a clinical stage biotechnology company developing a first-in-class therapeutic for peripheral…
— Approval based on results from global Phase III FRESCO-2 trial in patients with previously treated metastatic colorectal cancer — —…
Proceeds will be used to advance the Company’s IMANs into clinical trialsRaise underpins strong pre-clinical data demonstrating dual mechanism of…
BENTONVILLE, Ark., Sept. 23, 2024 /PRNewswire/ -- biophyle—a not-for-profit educational institution fostering collaboration between scientists and clinicians in Arkansas and…
Prior Phase 3 studies showed positive benefits in increasing unstimulated whole saliva secretionAinos aims to complete all regulatory approvals for…
New System Enhances Surgical Efficiency and Provides Versatile Solutions for Complex Spine ProceduresBELGRADE, MT / ACCESSWIRE / September 23, 2024…
– New data show istisociclib (KB-0742) triggered cell death in preclinical ovarian cancer models of platinum and PARP-inhibitor (PARPi) resistance –…
Press release OXFORD BIOMEDICA PLCINTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2024 Delivering Pure-Play CDMO Growth Strategy Continued…